← Back to Search

Local Anesthetic

Buffered Lidocaine for Prostate Cancer Biopsy Pain (BURN Trial)

Phase 1 & 2
Waitlist Available
Led By Alexander Zhu, DO
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years old or older
Biological males
Must not have
Neurological condition affecting pain or sensorium (ex. spinal cord injury, stroke, multiple sclerosis, etc)
Anorectal pathology precluding placement of a transrectal ultrasound
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 10 seconds of completing injection of all local anesthetic
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to see if Buffered Lidocaine can reduce pain during a prostate biopsy compared to regular Lidocaine. Participants will receive either Buffered Lidocaine or regular Lidocaine as a local

Who is the study for?
This trial is for men with prostate cancer who are scheduled to undergo a prostate biopsy. Participants must be willing to complete questionnaires about their pain and anxiety before and after the procedure. There's no specific exclusion criteria provided, but typically, patients with allergies to anesthetics or certain medical conditions may not qualify.
What is being tested?
The BURN Study is testing whether Buffered Lidocaine reduces pain during a prostate biopsy compared to standard 1% Lidocaine. Patients will receive one of these two local anesthetics at random and report their pain levels through questionnaires before and after the biopsy.
What are the potential side effects?
While specific side effects aren't listed, common reactions to lidocaine include temporary redness, swelling at the injection site, numbness beyond the target area, or in rare cases allergic reactions. Buffered solutions might reduce stinging on injection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am a biological male.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a neurological condition like spinal cord injury or MS.
Select...
I cannot have a transrectal ultrasound due to anorectal issues.
Select...
I have been diagnosed with chronic prostatitis, interstitial cystitis, or pelvic pain syndrome.
Select...
My prostate biopsy was done in the operating room.
Select...
My prostate biopsy was done under anesthesia that was more than just a local anesthetic.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 10 seconds of completing injection of all local anesthetic
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 10 seconds of completing injection of all local anesthetic for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pain of Local Anesthetic Injection
Secondary study objectives
Adverse Events
Pain of the Prostate Biopsy
Willingness to perform another prostate biopsy in the future, if medically necessary

Side effects data

From 2014 Phase 4 trial • 40 Patients • NCT01602692
40%
Nausea
10%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tumescent Solution With Dilute Epinephrine
Tumescent Solution With Dilute Lidocaine and Epinephrine

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Buffered LidocaineExperimental Treatment1 Intervention
1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio
Group II: 1% LidocaineActive Control1 Intervention

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,814 Previous Clinical Trials
1,912,733 Total Patients Enrolled
17 Trials studying Prostate Cancer
7,794 Patients Enrolled for Prostate Cancer
Alexander Zhu, DOPrincipal InvestigatorUniversity of Washington
~200 spots leftby Feb 2026